MFN-driven drug price reductions in the US are unlikely to have a big impact pharma R&D spending, experts agree.

Sanofi acquired commercialisation rights for the radiopharmaceutical AlphaMedix from Orana Med in September 2024.

Nanobiotix's JNJ-1900, which is in Phase III for HNSCC, exhibited an ORR of 69% in oesophageal cancer, potentially ...

SCYNEXIS has reported encouraging outcomes from a Phase I clinical trial of SCY-247, a second-generation triterpenoid antifungal being developed to treat and prevent invasive fungal infections.

Cognivia Signal will try to predict which patients are at risk of dropping out to give sponsors the opportunity to intervene.

Takeda will step away from cell therapy in favour of biologics, small molecules and ADCs in a “strategic portfolio prioritisation”.

The VESALIUS-CV trial (NCT03872401) has proved its long-term efficacy in these patients after meeting both its primary ...

Gilead and Arcus Biosciences’ anti-TIGIT mAb, domvanalimab, has demonstrated promising OS data during a Phase II trial in gastroesophageal adenocarinoma. Image credit: mi_viri via ShutterStock.com.

The vaccine was generally well tolerated among the paediatric population, with no unexpected safety signals reported. Credit: PeopleImages/Shutterstock.com. Bavarian ...

While overall survival (OS) is the king endpoint in oncology trials, it may be overshadowed by surrogates such as progression-free survival (PFS) and objective response rates (ORR) as outcomes improve ...

Eli Lilly announced the data from the OLE trial of Omvoh at United European Gastroenterology (UEG) Week in Berlin. Image credit: hapabapa / iStock Editorial via Getty Images Eli Lilly’s Omvoh ...